Private Market View

Medhionine

Ceuta, Spain · Founded 2022 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Bolboreta Innova Group.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Medhionine
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Medhionine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Medhionine

Provider of medical content and scientific communication services intended for translating complex biomedical information. The company provides digital content, academic writing, patient education materials, and visual storytelling, enabling healthcare and life sciences businesses to access personalized, accurate, and ethically guided medical communication.

Sector
Business Products and Services (B2B)
HQ
Ceuta, Spain
Founded
2022
Employees
19
Ownership
Privately Held (backing)
PA Mark — not yet priced

Medhionine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Medhionine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Medhionine in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.